Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine

Emma Kennedy; Roger Hewson; Stuart Dowall

doi:10.1007/978-1-0716-4338-9_19

Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine

Emma Kennedy, Roger Hewson, Stuart Dowall

Countermeasures Development & Evaluation Scientific Leaders

Research output: Contribution to journal › Article › peer-review

Abstract

One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.

Original language	English
Pages (from-to)	257-272
Number of pages	16
Journal	Methods in molecular biology (Clifton, N.J.)
Volume	2893
DOIs	https://doi.org/10.1007/978-1-0716-4338-9_19
Publication status	Published - 2025

Bibliographical note

Publisher Copyright:
© 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Publisher Copyright:
© The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 2025.

Keywords

Immunogenicity
Modified Vaccinia Ankara
Recombinant protein
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-0716-4338-9_19

Cite this

@article{f3cbdeaac93c4170a8411bd241c9ed5d,

title = "Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine",

abstract = "One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.",

keywords = "Immunogenicity, Modified Vaccinia Ankara, Recombinant protein, Vaccine",

author = "Emma Kennedy and Roger Hewson and Stuart Dowall",

note = "Publisher Copyright: {\textcopyright} 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature. Publisher Copyright: {\textcopyright} The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 2025.",

year = "2025",

doi = "10.1007/978-1-0716-4338-9\_19",

language = "English",

volume = "2893",

pages = "257--272",

journal = "Methods in molecular biology (Clifton, N.J.)",

issn = "1064-3745",

publisher = "Humana Press Inc.",

}

TY - JOUR

T1 - Recombinant Vaccine Production

T2 - Production of a Recombinant CCHF MVA Vaccine

AU - Kennedy, Emma

AU - Hewson, Roger

AU - Dowall, Stuart

N1 - Publisher Copyright: © 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature. Publisher Copyright: © The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 2025.

PY - 2025

Y1 - 2025

N2 - One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.

AB - One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.

KW - Immunogenicity

KW - Modified Vaccinia Ankara

KW - Recombinant protein

KW - Vaccine

UR - https://www.scopus.com/pages/publications/85212644833

U2 - 10.1007/978-1-0716-4338-9_19

DO - 10.1007/978-1-0716-4338-9_19

M3 - Article

C2 - 39671043

AN - SCOPUS:85212644833

SN - 1064-3745

VL - 2893

SP - 257

EP - 272

JO - Methods in molecular biology (Clifton, N.J.)

JF - Methods in molecular biology (Clifton, N.J.)

ER -

Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this